Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities

doi:10.3748/wjg.v28.i28.3573

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6114)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

391

WORD

104

HTML

3435

Figures (1-2)

592

Tables (1-3)

320

Sum=4842

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

158

Download

289

Sum=447

Publishing Process of This Article

Item

Count

Browse

320

Download

505

Sum=825

Jul 28, 2022 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jul 28, 2022; 28(28): 3573-3585
Published online Jul 28, 2022. doi: 10.3748/wjg.v28.i28.3573

Table 3 Clinical trials approaching combination of systemic treatment and intra-arterial actually enrolling, recruiting or waiting for final results

Trial	Trial registration	Drug	Control	n	Disease stage	Local treatment	Expected termination	Primary end-point
EMERALD-1	NCT03778957	Durvalumab + Bevacizumab plus TACE	TACE plusplacebo	600	Intermediate/advanced	TACE	2024	Progression-free survival
TACE-3	NCT04268888	Nivolumab plus DEB- TACE	DEB- TACE	522	Intermediate	DEB-TACE	2026	Overall survival
LEAP-012	NCT04246177	Lenvatinib plus Pembrolizumab plus cTACE	cTACE	950	Intermediate	Surgery/Ablation	2029	Overall survival and progression-free survival
CheckMate 74 W	NCT04340193	Nivolumab plusIpilimumab/placebo plus cTACE	cTACE plusplacebo	765	Intermediate	Surgery/Ablation	Non-available	Time-to-progression and overall survival

c: Conventional; DEB: Drug-eluting beads; TACE: Transarterial chemoembolization.

Citation: da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol 2022; 28(28): 3573-3585
URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3573.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i28.3573